Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6849841 | 0.98 | KDM4E (0.46) | KDM4EPDE4DCYP1A2TSHRSMN1; SMN2 | |
| SCHEMBL8719104 | 0.98 | KDM4E (0.46) | KDM4EPDE4DCYP1A2TSHRSMN1; SMN2 | |
| SCHEMBL9248449 | 0.81 | KDM4E (0.38) | KDM4EPDE4DTSHRSMN1; SMN2KMT2A | |
| SCHEMBL22372048 | 0.80 | TSHR (0.47) | KDM4ETSHRSMN1; SMN2GAALMNA | |
| SCHEMBL22372041 | 0.78 | PHLPP2 (0.46) | KDM4ECYP1A2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL9066023 | 0.77 | CYP3A4 (0.47) | KDM4ETSHRKMT2AMEN1ALDH1A1 | |
| SCHEMBL8115353 | 0.76 | CA12 (0.53) | KDM4ECYP1A2SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22372261 | 0.75 | JMJD6 (0.39) | — | |
| SCHEMBL30990056 | 0.75 | PDE4D (0.45) | KDM4EPDE4DCYP1A2KMT2AMEN1 | |
| SCHEMBL489524 | 0.74 | TSHR (0.52) | KDM4ECYP1A2TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118541458-A | Polishing liquid for CMP, storage liquid and polishing method | 株式会社力森诺科 | 2024-08-23 | — | — | CN | disclosed |
| CN-118488953-A | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | Calixis Inc. | 2024-08-01 | — | — | US | disclosed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-5744597-A | Stereoselective anion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides | ELI LILLY AND COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0577303-B1 | Stereoselective glycosylation process | LILLY CO ELI (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0577304-B1 | Stereoselective anion glycosylation process | LILLY CO ELI (US) | 1997-03-05 | — | — | EP | disclosed |
| CN-1085560-A | Stereoselective glycosylation process | LILLY CO ELI (US) | 1994-04-20 | — | — | CN | disclosed |
| EP-0577304-A1 | Stereoselective anion glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0577303-A1 | Stereoselective glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5144027-A | Cephalosporins, process for producing the same, intermediates thereof and process for producing the intermediates | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| US-4879381-A | ANTIBIOTICS | TOYOMA CHEMICAL COMPANY, LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| US-4673738-A | Novel intermediates of cephalosporins and process for producing 7-(substituted or unsubstituted amino)-3-substituted methyl-Δ3 -cephem-4-carboxylic acids | HANDI-PAC INC. (US) | 1987-06-16 | — | — | US | disclosed |
| US-4489072-A | BACTERICIDE, ANTIBIOTIC | TOYAMA CHEMICAL CO., LTD. (JP) | 1984-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | KDM4E 3895/4885PDE4D 2277/4885CYP1A2 4550/4885 |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | KDM4E 2738/4885PDE4D 1758/4885CYP1A2 464/4885 |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | KDM4E 2124/4885PDE4D 463/4885CYP1A2 30/4885 |
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | KIT, AURKC, PRKCE | KDM4E 719/4885PDE4D 931/4885CYP1A2 4125/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | KDM4E 3895/4885PDE4D 2277/4885CYP1A2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.